10-Q: Henry Schein Reports Q1 2026 Financial Results

Henry Schein, Inc. announced its first quarter 2026 financial results, with net sales increasing by 6.3% year-over-year.

Summary

• Henry Schein, Inc. reported net sales of $3,368 million for the three months ended March 28, 2026, a 6.3% increase compared to $3,168 million in the same period of 2025.
• Gross profit increased by 7.1% to $1,070 million, with a gross margin of 31.8%, up from 31.6% in the prior year.
• Operating income was $182 million, a slight increase from $175 million in the first quarter of 2025.
• Net income attributable to Henry Schein, Inc. was $107 million, or $0.92 per diluted share, compared to $110 million, or $0.88 per diluted share, in the prior year.
• The company experienced a net cash used in operating activities of $97 million, a decrease from $37 million provided by operating activities in the prior year, primarily due to changes in working capital.
• The company announced the appointment of Frederick M. Lowery as CEO, effective March 2, 2026, succeeding Stanley M. Bergman.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, with solid revenue growth driven by multiple segments and favorable currency, but offset by a slight dip in net income and a significant use of cash from operations due to working capital changes.

Positives

• Net sales increased by 6.3% to $3,368 million, driven by a 3.2% increase in internally generated sales and a 3.1% favorable foreign exchange impact.
• Gross profit increased by 7.1% to $1,070 million, with gross margin improving slightly to 31.8% from 31.6%.
• The Global Distribution and Value-Added Services segment saw a 6.1% increase in net sales, with dental merchandise sales up 9.0% and medical sales up 1.7%.
• Global Specialty Products net sales increased by 8.1%, with a 1.7% increase in internally generated local currency sales.
• Global Technology net sales increased by 7.0%, with a 6.9% increase in internally generated local currency sales, primarily due to cloud-based platform adoption.
• The company has $655 million available for future share repurchases under its authorized programs.

Negatives

• Net income attributable to Henry Schein, Inc. decreased slightly to $107 million from $110 million in the prior year.
• Diluted earnings per share decreased to $0.92 from $0.93 in the prior year.
• Net cash used in operating activities was $97 million, a significant decrease from $37 million provided by operating activities in the prior year, largely due to unfavorable changes in working capital.
• Accounts receivable days sales outstanding increased to 45.7 days from 44.1 days.
• Inventory turns decreased to 4.6 from 4.8.
• Restructuring and related costs were $12 million, down from $25 million in the prior year, but the company expects to incur further charges through 2027.
• Costs associated with shareholder advisory matters and select implementation related value creation consulting costs increased to $13 million from $8 million.

Risks

• Dependence on third parties for product manufacture and supply, and raw materials or components.
• Risks related to achieving strategic growth objectives and restructuring initiatives.
• Transitional challenges associated with acquisitions and joint ventures, including failure to achieve anticipated synergies.
• Cybersecurity risks, including potential cyberattacks or data security breaches.
• Intense competition and market consolidation.
• Political, economic, and regulatory influences on the healthcare industry.
• Changes in laws and policies governing manufacturing, development, and investment in countries where the company operates.
• Global macroeconomic and political conditions, including inflation, recession, and currency fluctuations.
• Failure to comply with existing and future regulatory requirements, including those related to healthcare fraud, anti-bribery, and data privacy.
• Risks associated with product liability, intellectual property, and other claims.
• Potential impacts from disease outbreaks, epidemics, or pandemics.
• Geopolitical risks, including war, terrorism, and public unrest.
• Supply chain disruptions and changes to international trade agreements.
• Litigation risks and new or unanticipated litigation developments.

Future Outlook

The company's cash and cash equivalents, access to private debt and public equity markets, and available credit facilities are believed to provide sufficient liquidity for currently foreseeable short-term and long-term capital needs. The company expects to continue recording restructuring and related charges through the end of 2027.

Management Comments

• The company believes it is positioned to capitalize on industry consolidation trends.
• The company believes demand for its products and services will grow while continuing to be impacted by current and future operating, economic and industry conditions.
• The company believes that its cash and cash equivalents, its ability to access private debt markets and public equity markets, and its available funds under existing credit facilities provide it with sufficient liquidity to meet its currently foreseeable short-term and long-term capital needs.

Industry Context

StockSavvy.ai notes that Henry Schein's performance aligns with broader healthcare industry trends of cost containment benefiting distributors and the growth of technology solutions for practice efficiency. The company's strategy of acquisitions and focus on value-added services positions it to navigate industry consolidation.

Management Changes

Legal Proceedings

• All remaining opioid-related lawsuits consolidated within the MultiDistrict Litigation (MDL) proceeding have been settled for immaterial amounts and dismissed.
• The company is involved in other legal proceedings, including product liability claims, employment matters, commercial disputes, and governmental inquiries, but none are currently anticipated to have a material adverse effect on financial position, liquidity, or results of operations.

Related Party Transactions

• A joint venture with Internet Brands (Henry Schein One, LLC) where Internet Brands holds a 33.6% noncontrolling interest.
• A ten-year royalty agreement with Internet Brands, with annual payments of approximately $31 million.
• Net payable balance to Internet Brands of $8 million as of March 28, 2026.
• Transactions with entities accounted for under the equity method, including sales and purchases.
• Leases for facilities from employees and minority shareholders, representing 7.0% of current and 7.9% of non-current operating lease liabilities as of March 28, 2026.

Stakeholder Impact

• Shareholders: Slight decrease in net income and EPS, but overall stable performance and continued share repurchase authorization.
• Employees: Impacted by restructuring and related costs, but also by new CEO appointment and stock-based compensation plans.
• Suppliers: Continued business relationships and potential impact from global trade policies and tariffs.
• Creditors: Company maintains significant debt levels, with covenants related to leverage ratios.
• Customers: Benefit from a broad range of products and services, and potential impact from industry consolidation and technology adoption.

Next Steps

• Continue integration of acquisitions.
• Execute on restructuring plan expected to be completed by the end of 2027.
• The Board intends to appoint a new Chairman promptly following the Companys 2026 annual meeting of stockholders.

Key Dates

Recommendation

The company shows steady revenue growth across its segments and a stable gross margin. However, the decrease in net income and EPS, coupled with a significant use of cash from operations due to working capital changes, warrants a cautious approach. The CEO transition and ongoing restructuring efforts also introduce some uncertainty. While the company's market position is strong, the current financial performance does not strongly signal a buy, nor does it indicate a sell. Therefore, a 'hold' recommendation is appropriate pending clearer signs of improved profitability and cash flow generation.

Keywords

Henry Schein, Form 10-Q, Quarterly Report, Financial Results, Net Sales, Gross Profit, Operating Income, Net Income, Earnings Per Share, Cash Flow, Healthcare Distribution, Dental Products, Medical Products, Technology Solutions, Acquisitions, Restructuring